Login to Your Account



Amgen's Lineup Of Heavy Hitters Scores In First-Quarter Earnings

By Randall Osborne


Thursday, April 24, 2003
Amgen Inc. reported positive results not only on its first-quarter balance sheet but also in the first of three Phase III trials with cinacalcet HCl, a drug for secondary hyperparathyroidism partnered with NPS Pharmaceuticals Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription